We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONTF
151
DELISTED
ON24
ONTF
| $236K | ﹤0.01% |
+30,009
| New | +$208K |
|
152
Select Water Solutions
WTTR
$2.34B
| $236K | ﹤0.01% |
+31,083
| New | +$231K |
|
153
MaxCyte
MXCT
$109M
| $235K | ﹤0.01% |
+50,031
| New | +$195K |
|
154
Zimmer Biomet
ZBH
$17.8B
| $233K | ﹤0.01% |
+1,918
| New | +$214K |
|
155
Becton Dickinson
BDX
$43.8B
| $231K | ﹤0.01% |
+949
| New | +$234K |
|
156
Illinois Tool Works
ITW
$81.9B
| $220K | ﹤0.01% |
+838
| New | +$201K |
|
157
Warner Bros
WBD
$63.4B
| $219K | ﹤0.01% |
+19,201
| New | +$207K |
|
158
Terreno Realty
TRNO
$7.72B
| $216K | ﹤0.01% |
+3,452
| New | +$196K |
|
159
Dominion Energy
D
$61.8B
| $211K | ﹤0.01% |
+4,495
| New | +$201K |
|
160
Golub Capital BDC
GBDC
$3.36B
| $211K | ﹤0.01% |
+13,955
| New | +$205K |
|
161
Main Street Capital
MAIN
$5B
| $210K | ﹤0.01% |
+4,856
| New | +$198K |
|
|
OSG
162
Octave Specialty Group
OSG
$258M
| $209K | ﹤0.01% |
+12,673
| New | +$176K |
|
|
ITCI
163
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $208K | ﹤0.01% |
+2,910
| New | +$167K |
|
164
Forward Air
FWRD
$466M
| $207K | ﹤0.01% |
+3,294
| New | +$222K |
|
165
Kohl's
KSS
$2.1B
| $207K | ﹤0.01% |
+7,207
| New | +$169K |
|
166
MGE Energy Inc
MGEE
$3.08B
| $207K | ﹤0.01% |
+2,856
| New | +$207K |
|
|
ARIS
167
DELISTED
Aris Water Solutions
ARIS
| $206K | ﹤0.01% |
+24,554
| New | +$211K |
|
|
VTLE
168
DELISTED
Vital Energy
VTLE
| $205K | ﹤0.01% |
+4,512
| New | +$216K |
|
169
Hewlett Packard
HPE
$63.8B
| $204K | ﹤0.01% |
+12,031
| New | +$196K |
|
170
OrthoPediatrics
KIDS
$509M
| $202K | ﹤0.01% |
+6,200
| New | +$180K |
|
171
Exelixis
EXEL
$14B
| $202K | ﹤0.01% |
+8,400
| New | +$183K |
|
172
Broadcom
AVGO
$1.82T
| $201K | ﹤0.01% |
+1,800
| New | +$170K |
|
173
ADMA Biologics
ADMA
$1.97B
| $193K | ﹤0.01% |
+42,657
| New | +$158K |
|
174
Huntington Bancshares
HBAN
$34.7B
| $187K | ﹤0.01% |
+14,701
| New | +$161K |
|
175
N-able
NABL
$823M
| $185K | ﹤0.01% |
+13,937
| New | +$177K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.